Elanco Animal Health(NYSE) ELAN

Elanco Animal Health Incorporated helps keep pets and livestock healthy. It makes medicines to prevent parasites and treat common animal diseases. These solutions help pets and improve farm food production.

Solutions for Pets and Farms

• Pet Health: Preventative treatments for parasites like fleas and ticks, along with vaccines and dermatology medicines; accounts for 52% of revenue.
• Farm Animal: Vaccines, antibiotics, and nutritional supplements for cattle, poultry, and swine; accounts for 47% of revenue.
• Contract Manufacturing: Production of medicines for third-party companies and royalties from human medical treatments; accounts for 1% of revenue.

Recent Moves and New Launches

• Acquired AHV on April 30, 2026, to expand its cattle product portfolio in Europe and the U.S.
• Launched Zenrelia in late 2024 as a medication to block itch-causing enzymes in dogs.
• Released Credelio Quattro in January 2025 as a monthly chewable tablet for canine parasite protection.
• Initiated a phased launch of Befrena in the second quarter of 2026 for canine skin allergies.
• Implemented a restructuring plan to exit specific livestock products and close older facilities in Germany and Kansas in 2026.
• Sold the rights to future royalties from a human medical treatment to Blackstone in May 2025 for $295 million to repay debt.

Where Elanco Gains an Edge

Elanco maintains a global footprint with products sold in more than 90 countries. The company uses an omnichannel strategy to reach customers through veterinary clinics, retail stores, and e-commerce platforms.

A Look at the Books

• Total revenue was $2.7 billion for the six-month period ended June 30, 2026, up 13% year over year.
• Net income was $111 million for the six-month period ended June 30, 2026, up 42% year over year.
• Market capitalization reached $12.3 billion in the second quarter of 2026, up 73% year over year.
• Pet health revenue reached $1.4 billion for the six-month period ended June 30, 2026, up 12% year over year.
• Cash provided by operating activities was $290 million for the six-month period ended June 30, 2026.

Bottom Line

Elanco has evolved from a legacy pharmaceutical division into a standalone provider of animal health solutions. The company prioritizes innovation in pet dermatology and sustainable livestock health to maintain its global market position.